Open access · CC-BY
via OpenAlex
The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review
Celeste M. Lavallee, Andreina Bruno, Christopher Ma, Maitreyi Raman
Nutrients · 2022 · ▲ 44 citations
Dysbiosis
Chronic inflammation
Disabled macroautophagy
Intermittent fasting
Human
Preclinical / animal
Review
Abstract
Intermittent fasting is a non-pharmacological dietary approach to management of obesity and metabolic syndrome, involving periodic intervals of complete or near-complete abstinence from food and energy-containing fluids. This dietary strategy has recently gained significant popularity in mainstream culture and has been shown to induce weight loss in humans, reduce gut and systemic inflammation, and improve gut microbial diversity and dysbiosis (largely in animal models). It has been hypothesized that intermittent fasting could be beneficial in the management of nonalcoholic fatty liver disease, given the condition's association with obesity. This review summarizes protocols, potential mechanisms of action, and evidence for intermittent fasting in nonalcoholic fatty liver disease. It also highlights practical considerations for implementing intermittent fasting in clinical practice. A search of the literature for English-language articles related to intermittent fasting or time-restricted feeding and liver disease was completed in PubMed and Google Scholar. Potential mechanisms of action for effects of intermittent fasting included modulation of circadian rhythm, adipose tissue and adipokines, gut microbiome, and autophagy(definition). Preclinical, epidemiological, and clinical trial data suggested clinical benefits of intermittent fasting on metabolic and inflammatory markers in humans. However, there was a paucity of evidence of its effects in patients with nonalcoholic fatty liver disease. More clinical studies are needed to determine mechanisms of action and to evaluate safety and efficacy of intermittent fasting in this population.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/nu14214655
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Lavallee, C.M., Bruno, A., Ma, C., & Raman, M. (2022). The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. <em>Nutrients</em>. https://doi.org/10.3390/nu14214655
Vancouver
Lavallee CM, Bruno A, Ma C, Raman M. The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. Nutrients. 2022. doi:10.3390/nu14214655.
BibTeX
@article{celeste2022TheRol,
title = {The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review},
author = {Celeste M. Lavallee and Andreina Bruno and Christopher Ma and Maitreyi Raman},
journal = {Nutrients},
year = {2022},
doi = {10.3390/nu14214655},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International journal of applied biology and forensic 2019
Open access · CC-BY
THE SCIENCE BEHIND INTERMITTENT FASTING
Journal of Gandhara Medical and Dental Science 2026
Open access · CC-BY
Physiological and Biochemical Effects of Intermittent Fasting on Insulin Sensitivity and Glucose Metabolism: A Systematic Review
Diabetes Obesity and Metabolism 2024
Open access · OA
Intermittent fasting for weight management and metabolic health: An updated comprehensive umbrella review of health outcomes
Archiv Euromedica 2025
Open access · OA
Intermittent fasting - its benefits and risks
JAMA Network Open 2021
Open access · CC-BY
Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials
The British Journal of Diabetes 2013
Open access · OA